Literature DB >> 16361247

Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.

Yukako Oheda1, Masaharu Kotani, Mai Murata, Hitoshi Sakuraba, Yoshito Kadota, Yutaka Tatano, Jun Kuwahara, Kohji Itoh.   

Abstract

Sialidosis and galactosialidosis are lysosomal storage diseases caused by the genetic defects of lysosomal sialidase (neuraminidase-1; NEU1) and lysosomal protective protein/cathepsin A (PPCA), respectively, associated with a NEU1 deficiency, excessive accumulation of sialylglycoconjugates, and development of progressive neurosomatic manifestations; in addition, the latter disorder is accompanied by simultaneous deficiencies of beta-galactosidase and cathepsin A. We demonstrated that a few soluble N-glycosylated proteins carrying sialyloligosaccharides sensitive to glycopeptidase F (GPF) can be specifically detected in cultured fibroblasts from sialidosis and galactosialidosis cases by blotting with a Maackia amurensis (MAM) lectin. We also examined the therapeutic effects of normal gene transfer and enzyme replacement by evaluating the decreases in sialylglycoconjugates accumulated in fibroblasts with these NEU1 deficiencies. The specific N-glycosylated proteins detected on MAM lectin blotting as well as the granular lysosomal fluorescence due to an avidin-FITC/biotinylated MAM lectin conjugate in sialidosis and galactosialidosis fibroblasts disappeared in parallel with the restoration of the intracellular NEU1 activity after transfection of the recombinant NEU1 fused to HA tag sequence and the wild-type PPCA cDNA as well as administration of the recombinant PPCA precursor protein. The detection method for the abnormal sialylglycoproteins in cultured cells involving MAM lectin was demonstrated to be useful not only for biochemical and diagnostic analyses of NEU1 deficiencies but also for therapeutic evaluation of these conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361247     DOI: 10.1093/glycob/cwj069

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  6 in total

1.  Synthesis and use of QCy7-derived modular probes for the detection and imaging of biologically relevant analytes.

Authors:  Orit Redy-Keisar; Einat Kisin-Finfer; Shiran Ferber; Ronit Satchi-Fainaro; Doron Shabat
Journal:  Nat Protoc       Date:  2013-12-05       Impact factor: 13.491

2.  Alteration of the neuronal and glial cell profiles in Neu1-deficient zebrafish.

Authors:  Asami Ikeda; Chiharu Yamasaki; Yurina Kubo; Yudai Doi; Mayu Komamizu; Masaharu Komatsu; Kazuhiro Shiozaki
Journal:  Glycoconj J       Date:  2022-07-25       Impact factor: 3.009

3.  Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein.

Authors:  Yuto Horii; Toshiki Iniwa; Masayoshi Onitsuka; Jun Tsukimoto; Yuki Tanaka; Hironobu Ike; Yuri Fukushi; Haruna Ando; Yoshie Takeuchi; So-Ichiro Nishioka; Daisuke Tsuji; Mariko Ikuo; Naoshi Yamazaki; Yoshiharu Takiguchi; Naozumi Ishimaru; Kohji Itoh
Journal:  Mol Ther Methods Clin Dev       Date:  2022-04-15       Impact factor: 5.849

4.  Impaired lysosomal trimming of N-linked oligosaccharides leads to hyperglycosylation of native lysosomal proteins in mice with alpha-mannosidosis.

Authors:  Markus Damme; Willy Morelle; Bernhard Schmidt; Claes Andersson; Jens Fogh; Jean-Claude Michalski; Torben Lübke
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

5.  Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases.

Authors:  Edina Poletto; Gabriela Pasqualim; Roberto Giugliani; Ursula Matte; Guilherme Baldo
Journal:  Genet Mol Biol       Date:  2019-05-23       Impact factor: 1.771

6.  Myoclonus generators in sialidosis.

Authors:  Felipe Vial; Patrick McGurrin; Sanaz Attaripour; Alesandra d'Azzo; Cynthia J Tifft; Camilo Toro; Mark Hallett
Journal:  Clin Neurophysiol Pract       Date:  2022-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.